This Clean Energy Penny Stock Has U.S. Military Backing. Should You Buy It Now?
At the end of May, Hyliion (HYLN) caught the market's eye with a breakthrough that turned the tide in its favor. The company secured selection from the Air Force and the Department of Defense's Chief Digital and Artificial Intelligence Office to meet a critical operational need.
Hyliion will supply its KARNO power modules which will help the Air Force maintain essential functions during fuel supply disruptions by effortlessly switching between available fuels. Investors reacted swiftly, sending HYLN stock up by 50% on May 28.
The 'Golden Era' for Tesla Starts June 22. Should You Buy TSLA Stock First?
3 Highly-Rated Dividend Stocks You've Probably Never Heard Of (But Should)
AMD Just Landed a New Microsoft Partnership. Should You Buy AMD Stock Here?
Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now!
Having earned status to directly support the Air Force, Hyliion now stands on firmer ground and can help the military's shift toward a more flexible and resilient energy framework.
With a significant catalyst behind it and a nearly 50% upside potential, how should you play HYLN stock here?
Hyliion (HYLN), is currently valued at $251 million. The company develops generators for stationary and mobile use. Its flagship KARNO generator operates on conventional fuels, landfill and wellhead gas, plus renewable hydrogen and ammonia, delivering versatile, efficient distributed power solutions across a wide range of energy sources.
Despite the broader market winds pushing against it, with a year-to-date decline of 47.5%, HYLN has now turned the tables. Over the past month, the stock has climbed by nearly 9%, in attempt to turnaround its story.
On May 13, Hyliion released its first-quarter earnings report for 2025, revealing results that fell short of Wall Street's projections. The company reported revenue of $489,000, primarily derived from research and development services under its contract with the Office of Naval Research. The figure lagged the anticipated $1.1 million.
The cost of revenue stood at $477,000, leading to a near-breakeven gross margin for the quarter. Operating expenses climbed 3.9% to $19.7 million, driven by an increase in R&D spending, which surged to $12.2 million from $8 million in Q1 2024. The jump reflected intensified activity in additive manufacturing, procurement of long-lead components, and escalating costs tied to ongoing development of KARNO Power Modules.
The bottom line showed net loss widening 10.7% to $17.3 million. Loss per share grew 11.1% year over year coming in at $0.10, missing the expected $0.08 per-share loss.
Consequently, the company now anticipates full-year 2025 cash outlays around $65 million, an increase from its previous $60 million guidance. Hyliion has maintained its full-year revenue guidance of $10 million to $15 million, propelled by KARNO module sales and ongoing R&D services, while projecting a year-end cash and investment balance near $155 million.
Analysts, meanwhile, foresee the Q2 loss per share widening by 50% to $0.09 and full-year 2025 losses increasing by 17.9% to $0.33. The outlook for 2026, however, shows a silver lining, with loss per share expected to narrow by 3% to $0.32.
Despite unveiling fresh developments and forging new collaborations, Hyliion finds itself grappling with sluggish revenue growth and mounting operational expenses. A single announcement of a military partnership, while promising, falls short of igniting strong investor confidence in the stock.
Currently, HYLN carries a 'Hold' consensus with only one analyst in coverage. That analyst has a price target of $2 on shares, representing upside potential of nearly 50%.
On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Vancouver company celebrating reusable food container success
started with just five stores but is now in institutions across Canada and the U.S. As Chad Pawson explains, local waste management officials say it's the type of private-sector ingenuity needed to address the region's garbage problem.
Yahoo
40 minutes ago
- Yahoo
Why Mondelez's Dividend Stands Strong in Uncertain Markets
Mondelez International, Inc. (NASDAQ:MDLZ) is one of the best dividend stocks for a bear market. Mondelez International, Inc. (NASDAQ:MDLZ) ranks among the top global snack makers and belongs to the consumer staples sector. During economic downturns, consumers typically continue buying food at consistent levels, and even tend to favor discounted options more, making large food companies like Mondelez appealing, especially when spending declines in more discretionary areas. A colourful array of products like candies, chocolates and gums on a supermarket shelf. Another reason investors are drawn to Mondelez International, Inc. (NASDAQ:MDLZ) is its strong dividend and reliable cash flow. In the latest quarter, the company generated $1.1 billion in operating cash flow and $0.8 billion in free cash flow, while returning $2.1 billion to shareholders through dividends and buybacks. Mondelez International, Inc. (NASDAQ:MDLZ) has also garnered attention on the dividend front. The company has been rewarding shareholders with growing dividends for the past 11 consecutive years. It offers a quarterly dividend of $0.47 per share and has a dividend yield of 2.83% The company has expressed confidence in its future earnings potential, which may support the strength and stability of its dividend payments. It has reaffirmed its outlook for the year, expecting organic net revenue to grow by around 5%. However, adjusted earnings per share are projected to decline by roughly 10% on a constant currency basis, mainly due to an unusual surge in cocoa prices. Despite this, the company anticipates generating over $3 billion in free cash flow for 2025. Since recessions often go hand in hand with falling stock markets, investors with shorter time horizons may find value in holding companies that offer steady or growing dividend yields. While we acknowledge the potential of MDLZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
40 minutes ago
- Yahoo
This Under-the-Radar Healthcare Stock Could Be a Solid Income Play
CVS Health Corporation (NYSE:CVS) is one of the best dividend stocks for a bear market. Even during economic downturns, people continue to rely on medications, essential consumer products, and affordable local healthcare. CVS Health Corporation (NYSE:CVS) serves as a convenient healthcare and retail destination within communities. A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products. The company's overall business remains solid, thanks to its diversified operations and multiple sources of revenue. In recent years, it has expanded its presence in primary care and launched a subsidiary called Cordavis to focus on developing and marketing biosimilar drugs. Its broad reach across communities and wide range of services are key advantages. Lately, higher Medicare usage and increased post-pandemic healthcare costs have impacted the company's revenue and earnings growth. However, CVS Health Corporation (NYSE:CVS) remains profitable and maintains a solid cash position. In the most recent quarter, it reported $4.6 billion in operating cash flow. Looking ahead to 2025, the company has raised its full-year operating cash flow forecast from around $6.5 billion to approximately $7.0 billion. In addition, CVS Health Corporation (NYSE:CVS) appears to have significant room to grow its dividend. With a cash payout ratio of just 30%, even doubling that figure would still leave it within a sustainable range. Due to this strong cash generation, CVS Health Corporation (NYSE:CVS) has maintained its payouts since 1997. Currently, it offers a quarterly dividend of $0.665 per share and has a dividend yield of 3.96%, as of June 17. While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.